Halozyme Therapeutics Inc. (HALO), a developer of drug-delivery systems, fell as much as 18 percent after its partner ViroPharma Inc. (VPHM) ended a mid-stage trial of a therapy for a genetic disease that causes severe swelling.
Halozyme dropped 15 percent to $7.21 at 9:33 a.m. New York time and fell as low as $7. ViroPharma lost 5.5 percent to $32.45. The trial’s cancellation was announced by the companies in statements today.
ViroPharma was running a clinical trial of a subcutaneous formulation of Cinryze, its drug to prevent the swelling attacks. Halozyme’s recombinant human hyaluronidase, or rHuPH20, was being combined with Cinryze for the subcutaneous treatment.
The treatment for hereditary angioedema was in the second of three phases of trials usually required before U.S. regulatory approval when some patients developed unexpected antibodies, Exton, Pennsylvania-based ViroPharma said. San Diego-based Halozyme said that the companies hadn’t seen any adverse effects, and called the halt a precaution.
“We support ViroPharma’s business decision,” Halozyme Chief Executive Officer Gregory Frost said in a statement.
Frost said he was confident of the drug’s safety profile.
A trail of recombinant human hyaluronidase was halted a year ago, as well, before being restarted.
To contact the editor responsible for this story: Reg Gale at firstname.lastname@example.org